FDA Approves Eflornithine to Reduce Risk of Relapse in ...
Eflornithine (Iwilfin) FDA-approved to reduce relapse risk in high-risk neuroblastoma patients post-therapy. Based on Study 3b and ANBL0032 trials, showing improved event-free and overall survival. Common adverse effects include otitis media, diarrhea, and cough.
Related Clinical Trials
Reference News
FDA approved eflornithine (Vaniqa) for high-risk neuroblastoma patients showing partial response to prior treatment. Study 3b, involving 105 patients, compared eflornithine's efficacy and safety against an external control, showing improved survival rates. Common side effects included diarrhea, infections, and laboratory abnormalities.
Eflornithine (Iwilfin) FDA-approved to reduce relapse risk in high-risk neuroblastoma patients post-therapy. Based on Study 3b and ANBL0032 trials, showing improved event-free and overall survival. Common adverse effects include otitis media, diarrhea, and cough.